GenSight Biologics wins 2016 Deloitte Technology Fast 50 “Biotech of the Future” Award for the Paris region

Paris, France, November 9, 2016 – GenSight Biologics (Euronext: SIGHT, FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, announces that Bernard Gilly, Chief Executive Officer, will present at the Stifel 2016 Healthcare Conference in New York (USA) on Tuesday, November 15, 2016 at 3:45 pm ET.

Contacts

GenSight Biologics Thomas Gidoin Chief Financial Officer ir@gensight-biologics.com +33 (0)1 76 21 72 20

NewCap Investor Relations Florent Alba gensight@newcap.eu +33 (0)1 44 71 98 55

Rooney Partners Media Relations Marion Janic mjanic@rooneyco.com +1-212-223-4017

---

Source: Gensight